N/A
Manufactured by Janssen Pharmaceuticals, Inc.
45,344 FDA adverse event reports analyzed
Last updated: 2026-04-14
PALIPERIDONE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Janssen Pharmaceuticals, Inc.. The most commonly reported adverse reactions for PALIPERIDONE include INJURY, GYNAECOMASTIA, DRUG INEFFECTIVE, ABNORMAL WEIGHT GAIN, OFF LABEL USE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for PALIPERIDONE.
Out of 22,766 classified reports for PALIPERIDONE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 45,344 FDA FAERS reports that mention PALIPERIDONE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include INJURY, GYNAECOMASTIA, DRUG INEFFECTIVE, ABNORMAL WEIGHT GAIN, OFF LABEL USE, WEIGHT INCREASED. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Janssen Pharmaceuticals, Inc. in connection with PALIPERIDONE. Always verify the specific product and NDC with your pharmacist.